Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
60
ENTX Quote, Financials, Valuation and Earnings
Last price:
$2.18
Seasonality move
:
78.56%
Day range:
$2.05 - $2.19
52-week range:
$0.52 - $3.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
11.42x
Volume:
142.2K
Avg. volume:
120K
1-year change:
234.62%
Market cap:
$73.7M
Revenue:
--
EPS (TTM):
-$0.26
Analysts' Opinion
-
Consensus RatingEntera Bio has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Entera Bio has an estimated upside of 400% from its current price of $2.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.18.
Fair Value
-
According to the consensus of 0 analysts, Entera Bio has 400% upside to fair value with a price target of -- per share.
ENTX vs. S&P 500
-
Over the past 5 trading days, Entera Bio has underperformed the S&P 500 by -9.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Entera Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Entera Bio revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Entera Bio reported revenues of $42K.
Earnings Growth
-
Entera Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Entera Bio reported earnings per share of -$0.08.
Enterprise value:
66.7M
EV / Invested capital:
10.35x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.38x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9K
Return On Assets:
-94.92%
Net Income Margin (TTM):
--
Return On Equity:
-113.4%
Return On Invested Capital:
-113.4%
Operating Margin:
-7192.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $285K | -- | -- | -- | $42K | |
| Gross Profit | $56K | $6K | $9K | -- | -- | |
| Operating Income | -$14M | -$10M | -$9.2M | -$2.4M | -$3M | |
| EBITDA | -$14M | -$9.9M | -$9.2M | -$2.4M | -$3M | |
| Diluted EPS | -$0.50 | -$0.34 | -$0.26 | -$0.08 | -$0.08 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.8M | $28.1M | $15.2M | $8M | $7.3M | |
| Total Assets | $8.8M | $29.1M | $15.5M | $8.6M | $7.7M | |
| Current Liabilities | $2.9M | $2.9M | $1.2M | $2M | $1.1M | |
| Total Liabilities | $3M | $3.1M | $1.2M | $2.3M | $1.3M | |
| Total Equity | $5.7M | $26M | $14.3M | $6.2M | $6.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13M | -$6.7M | -$8M | -$1.5M | -$2.2M | |
| Cash From Investing | -$109K | -$15K | -$5K | -- | -- | |
| Cash From Financing | -- | $5K | $7.3M | -- | $13K | |
| Free Cash Flow | -$13.1M | -$6.7M | -$8M | -$1.5M | -$2.2M | |
ENTX
Sector
Market Cap
$73.7M
$45.6M
Price % of 52-Week High
59.7%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
207.69%
-31.35%
Beta (5-Year)
1.548
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.14
200-day SMA
Buy
Level
$1.91
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$1.99
Relative Strength Index (RSI14)
Buy
Level
60.17
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-54.2169
50-day SMA
Buy
Level
$1.85
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
--
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The company's product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The company recently completed the phase 2 study for EB613. The company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
Stock Forecast FAQ
In the current month, ENTX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ENTX average analyst price target in the past 3 months is --.
-
Where Will Entera Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Entera Bio share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Entera Bio?
Analysts are divided on their view about Entera Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Entera Bio is a Sell and believe this share price will drop from its current level to --.
-
What Is Entera Bio's Price Target?
The price target for Entera Bio over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ENTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Entera Bio is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ENTX?
You can purchase shares of Entera Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Entera Bio shares.
-
What Is The Entera Bio Share Price Today?
Entera Bio was last trading at $2.18 per share. This represents the most recent stock quote for Entera Bio. Yesterday, Entera Bio closed at $2.18 per share.
-
How To Buy Entera Bio Stock Online?
In order to purchase Entera Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
